Technical Analysis for RGLS - Regulus Therapeutics Inc.

Grade Last Price % Change Price Change
grade F 1.04 -6.31% -0.07
RGLS closed down 6.31 percent on Friday, March 22, 2019, on 43 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
3 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical RGLS trend table...

Date Alert Name Type % Chg
Mar 22 Fell Below 50 DMA Bearish 0.00%
Mar 22 Wide Bands Range Expansion 0.00%
Mar 22 Oversold Stochastic Weakness 0.00%
Mar 21 50 DMA Support Bullish -6.31%
Mar 21 Narrow Range Bar Range Contraction -6.31%
Mar 21 Wide Bands Range Expansion -6.31%
Mar 21 Oversold Stochastic Weakness -6.31%
Mar 20 20 DMA Resistance Bearish -4.59%
Mar 20 Wide Bands Range Expansion -4.59%
Mar 20 Oversold Stochastic Weakness -4.59%

Older signals for RGLS ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Analyze My Stocks!
Configure default chart indicators
Basic chart:

Profile
Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat various diseases in the United States. The company utilizes its microRNA product platform to develop anti-miRs, a chemically modified single-stranded oligonucleotides. Its microRNA development candidates target miR-122 in hepatitis C virus infection; miR-21 and miR-221 in hepatocellular carcinoma; miR-21 in kidney fibrosis; miR-33 in atherosclerosis; and miR-10b in glioblastoma. The company has strategic alliances with AstraZeneca AB, GlaxoSmithKline plc, Sanofi, and Alnylam and Isis, as well as a strategic collaboration with Biogen Idec MA Inc. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
Biopharmaceutical Diseases Genetics Glioblastoma Regulus Therapeutics Isis Hepatocellular Carcinoma RNA Alnylam Pharmaceuticals Hepatitis C Virus Infection Atherosclerosis Microrna Nucleic Acids
Is RGLS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Mar 18 Regulus: 4Q Earnings Snapshot
Mar 18 Regulus Therapeutics beats by $0.16, misses on revenue
Mar 18 Regulus Reports Fourth Quarter and Year-End 2018 Financial Results and Recent Updates
Mar 15 Regulus Announces Transition of Research Leadership
Jan 7 Regulus Announces Clinical Candidate Nomination for the Treatment of Glioblastoma Multiforme
Jan 4 Regulus up 8% after hours on positive preclinical data on RGLS4326
Jan 4 Regulus Announces Preliminary Results of Planned Interim Data Analysis of RGLS4326 in New Mouse Chronic Toxicity Study
Dec 31 CNBC article highlights $35B market opportunity of NASH drugs
Dec 20 Need To Know: Regulus Therapeutics Inc. (NASDAQ:RGLS) Insiders Have Been Buying Shares
Dec 20 The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum
See more RGLS news...
Indicators
Indicator Value
52 Week High 10.08
52 Week Low 0.8
Average Volume 319,832
200-Day Moving Average 2.611
50-Day Moving Average 1.0761
20-Day Moving Average 1.1878
10-Day Moving Average 1.188
Average True Range 0.1419
ADX 22.73
+DI 23.2835
-DI 22.2004
Chandelier Exit (Long, 3 ATRs ) 1.1743
Chandelier Exit (Short, 3 ATRs ) 1.4057
Upper Bollinger Band 1.3873
Lower Bollinger Band 0.9883
Percent B (%b) 0.13
BandWidth 33.591514
MACD Line 0.0092
MACD Signal Line 0.0326
MACD Histogram -0.0234
Fundamentals Value
Market Cap 107.93 Million
Num Shares 104 Million
EPS -1.53
Price-to-Earnings (P/E) Ratio -0.68
Price-to-Sales 450.54
Price-to-Book 2.98
PEG Ratio -0.03
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.18
Resistance 3 (R3) 1.18 1.14 1.15
Resistance 2 (R2) 1.14 1.11 1.14 1.14
Resistance 1 (R1) 1.09 1.08 1.07 1.09 1.14
Pivot Point 1.05 1.05 1.04 1.05 1.05
Support 1 (S1) 1.00 1.02 0.98 1.00 0.94
Support 2 (S2) 0.96 0.99 0.96 0.94
Support 3 (S3) 0.91 0.96 0.93
Support 4 (S4) 0.91